Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Date publication

mai 2026

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suárez C, Maroto JP, Grünwald V, Oosting S, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Hartmann A, Bergmann L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42235464

Résumé

Papillary renal cell cancer (pRCC) represents the largest subgroup within non-clear cell (ncc) RCC. Compared with clear cell RCC (ccRCC), pRCC is considered less sensitive to currently available systemic therapies. Here, we report exploratory results from the pRCC subgroup of the SUNNIFORECAST trial comparing ipilimumab/nivolumab with standard of care (SOC) based on central pathological review.

Mots clés

Central pathological review, Immune checkpoint inhibitors, Ipilimumab, NccRCC, Nivolumab, Non–clear cell renal cell carcinoma, PD-L1 status, Papillary RCC, Tyrosine kinase inhibitors

Référence

Eur J Cancer. 2026 05 27;243:116816